Goy.boy.Hero
Humble superhero of the goys
- Joined
- Jun 28, 2026
- Posts
- 1,237
- Reputation
- 948
Basically my friend texted me: "My brother works in biotechnology and he js told me something his company figured out how to do, and thought it'd be interesting to u
They figured out how to successfully create mirror images of proteins used in performance enhancers, like just synthetically reversing their orientation
Allows them to operate basically undetected in the body, so they last magnitudes longer
According to him they're working on it alongside like 100 other companies
Still experimental tho, apparently if they mess up the protein synthesis even a little bit, it will invariably kill you, like a prion disease"
From what I understand, this means that if mirror-image peptide technology becomes practical and safe, it could mean:
Growth hormone and growth hormone-related peptides could last much longer, potentially reducing how often they need to be given.
Peptide drugs such as CJC-1295 or Ipamorelin might become more stable and effective if researchers can design versions that still activate the same receptors.
It could open the door to new peptide medicines that aren't currently practical because they're broken down too quickly.
However:
It wouldn't directly apply to anabolic-androgenic steroids (AAS) like testosterone, nandrolone, or trenbolone, because those are steroid molecules, not proteins or peptides.
They figured out how to successfully create mirror images of proteins used in performance enhancers, like just synthetically reversing their orientation
Allows them to operate basically undetected in the body, so they last magnitudes longer
According to him they're working on it alongside like 100 other companies
Still experimental tho, apparently if they mess up the protein synthesis even a little bit, it will invariably kill you, like a prion disease"
From what I understand, this means that if mirror-image peptide technology becomes practical and safe, it could mean:
Growth hormone and growth hormone-related peptides could last much longer, potentially reducing how often they need to be given.
Peptide drugs such as CJC-1295 or Ipamorelin might become more stable and effective if researchers can design versions that still activate the same receptors.
It could open the door to new peptide medicines that aren't currently practical because they're broken down too quickly.
However:
It wouldn't directly apply to anabolic-androgenic steroids (AAS) like testosterone, nandrolone, or trenbolone, because those are steroid molecules, not proteins or peptides.
